FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and
development of new Anti-TB drugs is of great importance. Since Kazakhstan is a country with
the high burden of tuberculosis, the Government of the Republic of Kazakhstan has founded
initiative on the development of new Anti-TB drug to treat drug-resistant forms of this
infectious disease. JSC "Scientific Center for Anti-infectious Drugs" has developed original
drug FS-1 for the treatment of multidrug resistant tuberculosis (MDR-TB).
Phase:
Phase 3
Details
Lead Sponsor:
Scientific Center for Anti-infectious Drugs, Kazakhstan
Collaborators:
Almaty City Tuberculosis Dispensary, Almaty, Kazakhstan Invivo laboratory, Kazakhstan Karaganda Medical University Ministry of Health, Kazakhstan National Center of Phthisiatry, Bishkek, Kyrgyzstan National Scientific Center of Phthisiopulmonology, Kazakhstan Phthisiopulmonology Center of Almaty, Kazakhstan Regional Anti-TB Dispensary of Karagandy Oblast, Kazakhstan Semey State Medical University West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan